Grifols (GRFS) Receivables - Other (2009 - 2025)
Grifols (GRFS) posted Receivables - Other of $117.6 million for Q4 2025, up 41.05% quarter-over-quarter from $83.4 million in Q4 2024, and up 41.05% year-on-year from $83.4 million in Q4 2024.
Grifols (GRFS) Receivables - Other (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Receivables - Other for 16 consecutive years, with $117.6 million the latest figure, recorded in Q4 2025.
- Receivables - Other for Q4 2025 came in at $117.6 million, up 41.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $117.6 million (up 41.05% YoY), and the FY2025 annual result was $117.6 million, up 41.05% from the prior year.
- Receivables - Other was $117.6 million for Q4 2025 at Grifols, up from $83.4 million in the prior quarter.
- Over five years, Receivables - Other peaked at $150.7 million in Q4 2021 and troughed at $74.7 million in Q4 2022.
- Average Receivables - Other over 5 years is $101.4 million, with a median of $83.4 million recorded in 2024.
- Year-over-year, Receivables - Other surged 74.72% in 2021 and sank 50.47% in 2022.
- Over 5 years, Receivables - Other stood at $150.7 million in 2021, then tumbled by 50.47% to $74.7 million in 2022, then climbed by 7.98% to $80.6 million in 2023, then advanced by 3.38% to $83.4 million in 2024, then jumped by 41.05% to $117.6 million in 2025.
- Per Business Quant data, the three most recent Receivables - Other figures were $117.6 million in Q4 2025, $83.4 million in Q4 2024, and $80.6 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 117.57 Mn |
| Dec 31, 2025 | 117.57 Mn |
| Dec 31, 2024 | 83.35 Mn |
| Dec 31, 2024 | 83.35 Mn |
| Dec 31, 2023 | 245.28 Mn |
| Dec 31, 2023 | 245.28 Mn |
| Dec 31, 2022 | 74.66 Mn |
| Dec 31, 2022 | 74.66 Mn |
| Dec 31, 2021 | 150.73 Mn |
| Dec 31, 2021 | 150.73 Mn |
| Dec 31, 2020 | 86.27 Mn |
| Dec 31, 2020 | 86.27 Mn |
| Dec 31, 2019 | 91.33 Mn |
| Dec 31, 2019 | 91.33 Mn |
| Dec 31, 2018 | 105.49 Mn |
| Dec 31, 2018 | 105.49 Mn |
| Jun 30, 2018 | 14.23 Mn |
| Jun 30, 2018 | 14.23 Mn |
| Dec 31, 2017 | 47.90 Mn |
| Dec 31, 2017 | 47.90 Mn |